Fabian Tenenbaum has served on the Board of Directors of Novasenta since 2025. Fabian brings over 20 years of leadership of executive management in biopharma, medical devices, and healthcare innovation, driving breakthrough therapies from early discovery to clinical and commercial success. As CEO and Board Member of Nectin Therapeutics, Fabian led the development of first-in-class immune checkpoint inhibitors and antibody-drug conjugate forging strategic partnerships with Immunome (NASDAQ: IMNM), and clinical collaborations with Merck and the MD Anderson Cancer Center. Previously, Fabian served as CEO of Bellerophon Therapeutics (NASDAQ: BLPH), advancing Phase 2/3 programs in pulmonary and fibrotic lung diseases. At Anterios Therapeutics, Fabian led the NASDAQ IPO process and steered the company to a $550M acquisition by Allergan. As co-founder and CEO of Syneron Beauty, he built a global aesthetics brand, secured FDA clearances, and acquisition by Unilever. Beyond his corporate leadership, Fabian served as a senior advisor to UPMC Enterprises, the innovation and venture capital arm of UPMC, a $26B healthcare leader. Fabian holds an MBA from Columbia Business School (Dean’s List) and a B.Md. from Ben Gurion University (Summa Cum Laude). He is an active member of the Latino Alumni Association of Columbia University.